```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research compound extensively utilized in thrombosis investigations. This antibody fragment selectively targets the glycoprotein IIb/IIIa binding site on platelets , inhibiting clot formation . Consequently , it's often investigated as a method to analyze the processes underlying coagulation and to determine the efficacy of antiplatelet medications . Availability is typically controlled to institutional settings.
```
The Abciximab Compound Research: Utilizing C7E3 and Compound 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently employs the monoclonal protein C7E3 and the chemical compound identified as 143653-53-6. These materials are essential for analyzing abciximab's mode of function, determining its therapeutic effect in various clinical settings, and elucidating potential predictors of therapeutic success. Further investigation leveraging these specific reagents is likely to yield valuable information for optimizing clinical applications related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Scientific Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent studies demonstrate that this antiplatelet agent (identified as 143653-53-6) presents significant investigative value, particularly when associated with C7E3. Initial findings indicated that this association might enhance therapeutic outcomes in multiple heart-related settings. Further copyrightination is directed on understanding the specific mode of action between the antiplatelet medication and C7E3, including analysis of blood clot cohesion and arterial protection.
- Ongoing research endeavors aim to maximize administration protocols.
- Animal approaches are being utilized to further assess such hypotheses.
- Clinical assessments are necessary to fully assess clinical efficacy.
```
Abciximab (C7E3) for Research: Quality and Details (143653-53-6)
Researchers requiring C7E3 for experimental research should carefully consider integrity and defined characteristics. The compound is typically offered as a solid powder and thorough analytical data including identity by LC-MS, potency assays, and bacterial endotoxin testing is available. Verify the supplier's CoA outlines defined ranges for related substances and meets established quality control guidelines.
High-Purity ReoPro Details & Supply
Acquiring research-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its origin . This glycoprotein is widely utilized in in vitro investigations , particularly those focused on platelet aggregation and clotting . Available sources offer this substance in varying amounts , typically ranging from g to substantial commercial quantities . Please suggest reviewing the report of analysis to verify integrity and suitability for your specific use . Moreover, ensure the shelf life date before Recombinant abciximab obtaining to maintain maximum performance .
- Standard Purity: >95%
- Storage Conditions: -20°C in suitable conditions
- Application : Platelet Adhesion Suppression Studies